Literature DB >> 20551193

Assessment of intravenous immunoglobulin non-responders in Kawasaki disease.

Ja-Young Hwang1, Kyung-Yil Lee, Jung-Woo Rhim, You-Sook Youn, Jin-Hee Oh, Ji-Whan Han, Joon-Sung Lee, David Burgner.   

Abstract

The authors compared pre-treatment and post-treatment characteristics of 206 prospectively enrolled patients with Kawasaki disease (KD) responsive to intravenous immunoglobulin (IVIG) with those of 23 (10% of total) IVIG non-responders. Demographic characteristics were similar in both groups. Compared to IVIG responders, non-responders had a longer total duration of fever and a higher incidence of coronary artery lesions. Prior to IVIG, non-responders had higher neutrophil differential and C-reactive protein, and lower cholesterol. 24 hours after the IVIG infusion, a total leucocyte count >13.1×10(9)/l, neutrophil differential >51% and total protein <72 g/l showed reasonable sensitivity (91%, 91% and 64%, respectively) and specificity (89%, 76% and 78%, respectively) as independent characteristics of non-response to IVIG. Laboratory parameters before and shortly after IVIG may reflect the severity of inflammation in KD patients and assist in informing further management.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20551193     DOI: 10.1136/adc.2010.184101

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  25 in total

1.  Paediatric rheumatology: Corticosteroids as primary therapy in Kawasaki disease.

Authors:  Rebecca Reindel; Stanford T Shulman
Journal:  Nat Rev Rheumatol       Date:  2012-05-01       Impact factor: 20.543

Review 2.  Use of corticosteroids during acute phase of Kawasaki disease.

Authors:  Jeong Jin Yu
Journal:  World J Clin Pediatr       Date:  2015-11-08

Review 3.  Treatment Options for Resistant Kawasaki Disease.

Authors:  Linny Kimly Phuong; Nigel Curtis; Peter Gowdie; Jonathan Akikusa; David Burgner
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

4.  Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?

Authors:  Pei-Ni Jone; Marsha S Anderson; Matthew J Mulvahill; Heather Heizer; Mary P Glodé; Samuel R Dominguez
Journal:  Pediatr Infect Dis J       Date:  2018-10       Impact factor: 2.129

5.  Epidemiology of immunoglobulin resistant Kawasaki disease: results from a large, national database.

Authors:  Brady S Moffett; Dorothy Syblik; Susan Denfield; Carolyn Altman; Kristin Tejtel-Sexson
Journal:  Pediatr Cardiol       Date:  2014-09-02       Impact factor: 1.655

6.  IgG levels in Kawasaki disease and its association with clinical outcomes.

Authors:  Marco Antonio Yamazaki-Nakashimada; Luisa Berenise Gámez-González; Chiharu Murata; Takafumi Honda; Kumi Yasukawa; Hiromichi Hamada
Journal:  Clin Rheumatol       Date:  2018-10-20       Impact factor: 2.980

Review 7.  Kawasaki disease: laboratory findings and an immunopathogenesis on the premise of a "protein homeostasis system".

Authors:  Kyung-Yil Lee; Jung-Woo Rhim; Jin-Han Kang
Journal:  Yonsei Med J       Date:  2012-03       Impact factor: 2.759

8.  Prediction of resistance to standard intravenous immunoglobulin therapy in kawasaki disease.

Authors:  Sang Min Lee; Jeong Bong Lee; Young Bin Go; Ho Young Song; Byung Jin Lee; Ji Hee Kwak
Journal:  Korean Circ J       Date:  2014-11-25       Impact factor: 3.243

9.  Prediction of unresponsiveness to second intravenous immunoglobulin treatment in patients with Kawasaki disease refractory to initial treatment.

Authors:  Euri Seo; Jeong Jin Yu; Hyun Ok Jun; Eun Jung Shin; Jae Suk Baek; Young-Hwue Kim; Jae-Kon Ko
Journal:  Korean J Pediatr       Date:  2016-10-17

10.  Unique Molecular Patterns Uncovered in Kawasaki Disease Patients with Elevated Serum Gamma Glutamyl Transferase Levels: Implications for Intravenous Immunoglobulin Responsiveness.

Authors:  Yue Wang; Zhen Li; Guang Hu; Shiying Hao; Xiaohong Deng; Min Huang; Miao Ren; Xiyuan Jiang; John T Kanegaye; Kee-Soo Ha; JungHwa Lee; Xiaofeng Li; Xuejun Jiang; Yunxian Yu; Adriana H Tremoulet; Jane C Burns; John C Whitin; Andrew Y Shin; Karl G Sylvester; Doff B McElhinney; Harvey J Cohen; Xuefeng B Ling
Journal:  PLoS One       Date:  2016-12-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.